Lifetime cost-effectiveness and equity impacts of the Healthy Primary School of the Future initiative.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
09 Dec 2020
Historique:
received: 24 08 2020
accepted: 21 10 2020
entrez: 10 12 2020
pubmed: 11 12 2020
medline: 28 4 2021
Statut: epublish

Résumé

This study estimated the lifetime cost-effectiveness and equity impacts associated with two lifestyle interventions in the Dutch primary school setting (targeting 4-12 year olds). The Healthy Primary School of the Future (HPSF; a healthy school lunch and structured physical activity) and the Physical Activity School (PAS; structured physical activity) were compared to the regular Dutch curriculum (N = 1676). An adolescence model, calculating weight development, and the RIVM Chronic Disease Model, calculating overweight-related chronic diseases, were linked to estimate the lifetime impact on chronic diseases, quality adjusted life years (QALYs), healthcare, and productivity costs. Cost-effectiveness was expressed as the additional costs/QALY gained and we used €20,000 as threshold. Scenario analyses accounted for alternative effect maintenance scenarios and equity analyses examined cost-effectiveness in different socioeconomic status (SES) groups. HPSF resulted in a lifetime costs of €773 (societal perspective) and a lifetime QALY gain of 0.039 per child versus control schools. HPSF led to lower costs and more QALYs as compared to PAS. From a societal perspective, HPSF had a cost/QALY gained of €19,734 versus control schools, 50% probability of being cost-effective, and beneficial equity impact (0.02 QALYs gained/child for low versus high SES). The cost-effectiveness threshold was surpassed when intervention effects decayed over time. HPSF may be a cost-effective and equitable strategy for combatting the lifetime burden of unhealthy lifestyles. The win-win situation will, however, only be realised if the intervention effect is sustained into adulthood for all SES groups. Clinicaltrials.gov ( NCT02800616 ). Registered 15 June 2016 - Retrospectively registered.

Sections du résumé

BACKGROUND BACKGROUND
This study estimated the lifetime cost-effectiveness and equity impacts associated with two lifestyle interventions in the Dutch primary school setting (targeting 4-12 year olds).
METHODS METHODS
The Healthy Primary School of the Future (HPSF; a healthy school lunch and structured physical activity) and the Physical Activity School (PAS; structured physical activity) were compared to the regular Dutch curriculum (N = 1676). An adolescence model, calculating weight development, and the RIVM Chronic Disease Model, calculating overweight-related chronic diseases, were linked to estimate the lifetime impact on chronic diseases, quality adjusted life years (QALYs), healthcare, and productivity costs. Cost-effectiveness was expressed as the additional costs/QALY gained and we used €20,000 as threshold. Scenario analyses accounted for alternative effect maintenance scenarios and equity analyses examined cost-effectiveness in different socioeconomic status (SES) groups.
RESULTS RESULTS
HPSF resulted in a lifetime costs of €773 (societal perspective) and a lifetime QALY gain of 0.039 per child versus control schools. HPSF led to lower costs and more QALYs as compared to PAS. From a societal perspective, HPSF had a cost/QALY gained of €19,734 versus control schools, 50% probability of being cost-effective, and beneficial equity impact (0.02 QALYs gained/child for low versus high SES). The cost-effectiveness threshold was surpassed when intervention effects decayed over time.
CONCLUSIONS CONCLUSIONS
HPSF may be a cost-effective and equitable strategy for combatting the lifetime burden of unhealthy lifestyles. The win-win situation will, however, only be realised if the intervention effect is sustained into adulthood for all SES groups.
TRIAL REGISTRATION BACKGROUND
Clinicaltrials.gov ( NCT02800616 ). Registered 15 June 2016 - Retrospectively registered.

Identifiants

pubmed: 33297992
doi: 10.1186/s12889-020-09744-9
pii: 10.1186/s12889-020-09744-9
pmc: PMC7724829
doi:

Banques de données

ClinicalTrials.gov
['NCT02800616']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1887

Subventions

Organisme : Limburg Provincial Authorities
ID : 200130003
Organisme : Friesland Campina
ID : LLMV00

Références

Health Econ. 2020 May;29(5):624-639
pubmed: 32090412
Prev Sci. 2018 Aug;19(6):716-727
pubmed: 29856040
Obes Rev. 2017 Dec;18(12):1412-1424
pubmed: 28925105
J Epidemiol Community Health. 2013 Feb;67(2):190-3
pubmed: 22875078
BMC Public Health. 2019 Jun 6;19(1):698
pubmed: 31170941
Nutrients. 2019 Mar 22;11(3):
pubmed: 30909515
BMJ. 2000 May 6;320(7244):1240-3
pubmed: 10797032
Health Aff (Millwood). 2015 Nov;34(11):1932-9
pubmed: 26526252
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
Int J Behav Nutr Phys Act. 2007 Oct 01;4:47
pubmed: 17908315
PLoS One. 2011;6(11):e27608
pubmed: 22110687
Eur J Health Econ. 2018 Sep;19(7):993-1008
pubmed: 29260341
Am J Prev Med. 2013 Jun;44(6):e57-66
pubmed: 23683991
J Epidemiol Community Health. 2019 Feb;73(2):136-141
pubmed: 30478145
Value Health. 2017 Feb;20(2):206-212
pubmed: 28237196
BMC Public Health. 2016 Jul 26;16:639
pubmed: 27456845
Ned Tijdschr Geneeskd. 2013;157(52):A6507
pubmed: 24382034
Br J Gen Pract. 2009 Nov;59(568):e353-8
pubmed: 19656444
BMC Med. 2013 Mar 25;11:80
pubmed: 23531108
Int J Obes (Lond). 2011 Jul;35(7):891-8
pubmed: 20975725
Eur J Epidemiol. 2015 May;30(5):357-95
pubmed: 25837965
Obesity (Silver Spring). 2006 Sep;14(9):1481-2
pubmed: 17030956
BMJ Open. 2019 Oct 31;9(10):e030676
pubmed: 31676651
J Occup Environ Med. 2014 Jan;56(1):20-7
pubmed: 24351899
Math Med Biol. 2010 Mar;27(1):1-19
pubmed: 19516046
PLoS One. 2020 Jun 19;15(6):e0234804
pubmed: 32559212

Auteurs

Marije Oosterhoff (M)

Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center MUMC+/ Care and Public Health Research Institute (CAPHRI), Maastricht University, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands. marije.oosterhoff@maastrichtuniversity.nl.

Eelco A B Over (EAB)

Centre for Nutrition, Prevention and Health Services, National Institute of Public Health and the Environment, Bilthoven, the Netherlands.

Anoukh van Giessen (A)

Centre for Nutrition, Prevention and Health Services, National Institute of Public Health and the Environment, Bilthoven, the Netherlands.

Rudolf T Hoogenveen (RT)

Expertise Center for Methodology and Information Services, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.

Hans Bosma (H)

Department of Social Medicine, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.

Onno C P van Schayck (OCP)

Department of Family Medicine, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.

Manuela A Joore (MA)

Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center MUMC+/ Care and Public Health Research Institute (CAPHRI), Maastricht University, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH